Table 3.

Primary and secondary outcomes between patients receiving an oral antiviral drug (molnupiravir or nirmatrelvir/ritonavir) versus patients not receiving an oral antiviral drug from the propensity-matched cohort of patients 65 years of age or older.

Outcomes	Patients who received an oral antiviral (n=1370)	Patients who did not receive an oral antiviral (n=1370)	Odds ratio (95% Confidence Interval)	p-value
Primary Outcome
Admission or Death within 30 days	65 (4.75%)	139 (10.2%)	0.44 (0.32 to 0.60)	<0.0001
Secondary Outcome
Admission within 30 days	61 (4.46%)	106 (7.74%)	0.56 (0.40-0.77)	0.0003
Death within 30 days	8 (0.58%)	43 (3.14%)	0.18 (0.08-0.39)	<0.0001